Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan.

Eades, William; Liu, William; Shen, Yue; Shi, Zhanquan; Yan, Bingfang

Eades, William; Liu, William; Shen, Yue; Shi, Zhanquan; Yan, Bingfang.

Afiliação

Eades W; Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA.
Liu W; Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA.
Shen Y; Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA.
Shi Z; Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA.
Yan B; Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA.

Curr Drug Metab ; 2022 Dec 12.

Article em En | MEDLINE | ID: mdl-36515038

Palavras-chave

Diarrhea; Gastrointestinal adverse effect; Intestinal organoids.; Irinotecan; Remdesivir; Sofosbuvir

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Curr Drug Metab Assunto da revista: METABOLISMO / QUIMICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google